Skip to main content

Central Lab, Bioanalytical Lab and R&D Lab

GCCL Expands Asia-Pacific Reach as Platinum Sponsor at ABP 2026

Image
GCCL Expands Asia-Pacific Reach as Platinum Sponsor at ABP 2026

Yongin, South Korea – September 11, 2026 -- GCCL (Global Clinical Central Lab), a South Korea-based clinical trial sample analysis provider, sponsored the Asia Bio Partnering Forum 2026 (ABP 2026) as a Platinum Sponsor, using the Singapore event to pursue expansion of its assay development and clinical sample analysis services across the Asia-Pacific region.

GCCL held partnering meetings with drug developers across mRNA, radiopharmaceutical and antibody therapy segments

The forum, held in Singapore from August 31 to September 2, drew approximately 650 pharmaceutical and biotechnology industry professionals, investors and life sciences stakeholders, generating roughly 2,500 one-on-one partnering meetings. GCCL engaged drug developers working across mRNA and nucleic acid therapeutics, radiopharmaceuticals and antibody-based therapies to assess evolving analytical requirements in global clinical development.

GCCL Sponsors ABP 2026 to Expand Asia-Pacific Clinical Lab Services

Image
GCCL Sponsors ABP 2026 to Expand Asia-Pacific Clinical Lab Services

Yongin, South Korea – September 10, 2026 -- GCCL (Global Clinical Central Lab), a South Korea-based clinical trial sample analysis provider, served as a Platinum Sponsor at the Asia Bio Partnering Forum 2026 (ABP 2026) in Singapore, held from August 31 to September 2, as it pursued expansion of its assay development and sample analysis services across the Asia-Pacific region.

ABP 2026 drew 650 industry professionals and 2,500 one-on-one partnering meetings

The forum brought together approximately 650 pharmaceutical and biotechnology executives, investors and life sciences stakeholders, with roughly 2,500 one-on-one partnering meetings held over three days. GCCL used the event to hold discussions with drug developers, contract research organizations (CROs) and regional stakeholders from Korea, China, Japan, Singapore, Vietnam and Europe.